FDA gives LYT-200 fast track status as potential AML treatment
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Puretech Health’s LYT-200, an investigative treatment for acute myeloid leukemia…
Marisa Wexler, MS, senior science writer—
Articles by Marisa Wexler
Antipsychotic clozapine raises blood cancer rates; overall risk is small
Treatment with the antipsychotic medication clozapine may increase the risk of blood cancers, but their overall likelihood is still low in people taking the drug,…
Chimerix asks FDA to approve oral dordaviprone as glioma treatment
Chimerix has submitted an application asking the U.S. Food and Drug Administration (FDA) to approve its oral therapy dordaviprone as a treatment for recurrent…
Glioma therapy THIO granted FDA rare pediatric disease designation
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to the anti-cancer agent THIO as a potential treatment for an uncommon…
Gut microbiome tied to therapy response in recurrent ovarian cancer
A person’s microbiome, or the collection of all microorganisms that live in the gut, can enhance the body’s antitumor response and lead to better treatment…
Cell therapy anito-cel shows promise for hard-to-treat RRMM
Most people with relapsed or refractory multiple myeloma (RRMM) given the cell therapy anitocabtagene autoleucel — known as anito-cel — in a Phase 2…
Carvykti delays myeloma symptom worsening, per Phase 3 trial data
The cell therapy Carvykti (ciltacabtagene autoleucel) — approved earlier this year as a second-line treatment for people with multiple myeloma — was shown to delay…
Vitamin D seen to prevent ovarian cancer’s onset in disease models
Vitamin D may help to prevent the development of ovarian cancers, according to new studies in mice and cell disease models. “These data strongly…
Scientists discover tissue differences in brain cancer in children
U.S. scientists have discovered that pediatric low-grade gliomas — a type of brain cancer that can occur in children — are generally softer than normal…
Survival better with Blenrep combo than Darzalex for R/R myeloma
A combination therapy using Blenrep (belantamab mafodotin) was more effective at extending life in people with relapsed or refractory multiple myeloma than a combo treatment…
